CRO Services Market: Growth in Developing Regions
- The Contract Research Organization (CRO) services market is poised for substantial expansion, projecting a rise from $68.3 billion in 2022 to an estimated $115.1 billion by 2027. This...
- A key factor fueling this growth is the increasing investment in pharmaceutical research and advancement.
- Despite the COVID-19 pandemic, the pharmaceutical industry has continued to thrive, with the U.S.
The Contract Research Organization (CRO) services market is set for robust growth, with projections soaring to $115.1 billion by 2027,fueled by rising pharmaceutical R&D investments and a CAGR of 11.0%. Clinical research services dominate the market, driven by escalating expenditures on new drug development and the costs of clinical trials. Oncology leads as the largest therapeutic area, reflecting increased initiatives targeting cancer. The Asia-Pacific region is witnessing the fastest expansion, bolstered by a burgeoning pharmaceutical industry, favorable policies, and lower clinical trial expenses. Major players—IQVIA, LabCorp, and others—are capitalizing on this growth. Stay informed with News Directory 3 to understand how the CRO landscape is evolving. Discover what’s next and how developing regions will shape the future of this market.
contract Research Organization Services Market to See Robust Growth Through 2027
The Contract Research Organization (CRO) services market is poised for substantial expansion, projecting a rise from $68.3 billion in 2022 to an estimated $115.1 billion by 2027. This represents an annual compound growth rate (CAGR) of 11.0%.
A key factor fueling this growth is the increasing investment in pharmaceutical research and advancement. Pharmaceutical companies are allocating important resources to develop innovative drugs and medical devices. Global pharmaceutical R&D spending, which stood at $137 billion in 2012 and $212 billion in 2021, is projected to reach $254 billion by 2026, according to an EvaluatePharma report. This escalating investment is expected to drive the outsourcing of research services to CROs by pharmaceutical, biotechnology, and academic organizations.
Despite the COVID-19 pandemic, the pharmaceutical industry has continued to thrive, with the U.S. Food and Drug Administration (FDA) approving 53 drugs in 2020. This robust performance, second only to 2018, underscores the industry’s resilience and commitment to innovation. The increasing number of biologics and biosimilars in development further contributes to the demand for CRO services.
Clinical research services constitute the largest segment within the CRO services market. This dominance is attributed to the rising R&D expenditure on new drugs and the high costs associated with conducting clinical trials.
Within therapeutic areas, oncology represents the largest segment in the CRO services market. The increasing number of drug discovery initiatives targeting cancer and the rising global prevalence of cancer contribute to this segment’s prominence.
The Asia-Pacific region is anticipated to experience the fastest growth in the CRO services market. Factors such as the region’s rapidly expanding pharmaceutical industry, favorable government policies, increasing establishment of manufacturing facilities, and lower clinical trial costs contribute to this growth.
Key players in the contract research organization services market include IQVIA Inc., laboratory Corporation of America Holdings, PPD, Inc. (Now a part of Thermo Fisher Scientific Inc.), ICON plc, Syneos Health, Inc., Parexel International Corporation, and Charles River Laboratories International Inc.
What’s next
The Contract Research Organization (CRO) services market is expected to maintain its upward trajectory, driven by continued investment in pharmaceutical R&D, increasing drug approvals, and the expansion of the pharmaceutical industry in emerging markets. The Asia-Pacific region, in particular, is poised to offer significant growth opportunities for CROs.